Syngene Manufacturing Solutions Limited (SMSL), a wholly-owned subsidiary company of Syngene International Limited, was incorporated on August 26, 2022.

The company has an authorised capital of 5,00,00,000 equity shares of Rs. 10 each aggregating to Rs. 50,00,00,000 and subscribed capital of 10,00,000 equity shares of Rs. 10 each aggregating to Rs. 1,00,00,000. 

SMSL shall be engaged in the business of manufacturing of pharmaceutical, bio-pharmaceutical, and biological products of any kind.

Syngene International Ltd. is an integrated research, development and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors.

With a combination of dedicated research facilities for Amgen, Baxter, and Bristol-Myers Squibb as well as two million square feet of specialist discovery, development and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including GSK, Zoetis, and Merck KGaA.